Cargando…
2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial
BACKGROUND: Antibiotic resistance in pediatrics, including neonates and infants, is increasing globally. Ceftazidime-avibactam (CAZ-AVI) is approved for use in pediatric patients (age ≥ 3 months) with Gram-negative bacterial infections. This study evaluated pharmacokinetics (PK), safety, and efficac...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678973/ http://dx.doi.org/10.1093/ofid/ofad500.2473 |
_version_ | 1785150483711655936 |
---|---|
author | Bradley, John S Roilides, Emmanuel England, Richard Tawadrous, Margaret Yan, Jean Soto, Elena Stone, Gregory Kamat, Shweta |
author_facet | Bradley, John S Roilides, Emmanuel England, Richard Tawadrous, Margaret Yan, Jean Soto, Elena Stone, Gregory Kamat, Shweta |
author_sort | Bradley, John S |
collection | PubMed |
description | BACKGROUND: Antibiotic resistance in pediatrics, including neonates and infants, is increasing globally. Ceftazidime-avibactam (CAZ-AVI) is approved for use in pediatric patients (age ≥ 3 months) with Gram-negative bacterial infections. This study evaluated pharmacokinetics (PK), safety, and efficacy of CAZ-AVI in hospitalized neonates and young infants (from 26 weeks gestation, up to 3 months of age) with suspected/confirmed infections due to Gram-negative pathogens requiring intravenous (IV) antibiotic treatment (Tx). METHODS: This Phase 2a study was conducted at 39 sites in 9 countries (Jan2020-Dec2022; EudraCT 2018-002800-16). Hospitalized neonates and infants received single (Part A) or multiple doses (Part B) of IV CAZ-AVI (Figure 1). PK (CAZ and AVI), safety (adverse events [AEs], serious AEs, deaths), and efficacy (Part B: clinical outcomes [cure/improvement], microbiological response) were assessed. The study was not powered for inferential statistical analysis, descriptive methods were used to summarize all data. [Figure: see text] RESULTS: In total, 46 participants were administered CAZ-AVI, aged 2 to 89 days and 31 to ≥ 37 weeks gestation (Table 1). Overall, sepsis (39.1%) and urinary tract infection (15.2%) were the most common primary infectious diagnoses. In Part B, 60% of the baseline pathogens isolated were Escherichia coli. Median duration of CAZ-AVI Tx in Part B was 7.0 days. Plasma concentrations of CAZ and AVI were similar to those in previous pediatric studies (Figure 2). Overall, 50% (n=23) of participants had treatment-emergent AEs (TEAEs); the majority were mild/moderate in severity. SAEs (n=8) and deaths (due to necrotizing enterocolitis and septic shock, n=1; sepsis, n=1) were not related to study Tx. Most participants had favorable clinical outcomes and microbiological response at test of cure. [Figure: see text] [Figure: see text] CONCLUSION: Plasma concentrations of CAZ and AVI after single and multiple doses of CAZ-AVI were similar to previous pediatric studies. Single and multiple doses of CAZ-AVI were safe and well tolerated in hospitalized neonates and young infants with suspected/confirmed bacterial infections. TEAEs were mild/moderate in severity and no new safety concerns were identified. DISCLOSURES: Emmanuel Roilides, MD, PhD, Gilead: Advisor/Consultant|GSK: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|Mundipharma: Advisor/Consultant|Pfizer: Grant/Research Support|Scynexis: Grant/Research Support Richard England, MD, PhD, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Margaret Tawadrous, MD, MS, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Jean Yan, M.S., Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Elena Soto, PhD, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Gregory Stone, PhD, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Shweta Kamat, MD, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds |
format | Online Article Text |
id | pubmed-10678973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106789732023-11-27 2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial Bradley, John S Roilides, Emmanuel England, Richard Tawadrous, Margaret Yan, Jean Soto, Elena Stone, Gregory Kamat, Shweta Open Forum Infect Dis Abstract BACKGROUND: Antibiotic resistance in pediatrics, including neonates and infants, is increasing globally. Ceftazidime-avibactam (CAZ-AVI) is approved for use in pediatric patients (age ≥ 3 months) with Gram-negative bacterial infections. This study evaluated pharmacokinetics (PK), safety, and efficacy of CAZ-AVI in hospitalized neonates and young infants (from 26 weeks gestation, up to 3 months of age) with suspected/confirmed infections due to Gram-negative pathogens requiring intravenous (IV) antibiotic treatment (Tx). METHODS: This Phase 2a study was conducted at 39 sites in 9 countries (Jan2020-Dec2022; EudraCT 2018-002800-16). Hospitalized neonates and infants received single (Part A) or multiple doses (Part B) of IV CAZ-AVI (Figure 1). PK (CAZ and AVI), safety (adverse events [AEs], serious AEs, deaths), and efficacy (Part B: clinical outcomes [cure/improvement], microbiological response) were assessed. The study was not powered for inferential statistical analysis, descriptive methods were used to summarize all data. [Figure: see text] RESULTS: In total, 46 participants were administered CAZ-AVI, aged 2 to 89 days and 31 to ≥ 37 weeks gestation (Table 1). Overall, sepsis (39.1%) and urinary tract infection (15.2%) were the most common primary infectious diagnoses. In Part B, 60% of the baseline pathogens isolated were Escherichia coli. Median duration of CAZ-AVI Tx in Part B was 7.0 days. Plasma concentrations of CAZ and AVI were similar to those in previous pediatric studies (Figure 2). Overall, 50% (n=23) of participants had treatment-emergent AEs (TEAEs); the majority were mild/moderate in severity. SAEs (n=8) and deaths (due to necrotizing enterocolitis and septic shock, n=1; sepsis, n=1) were not related to study Tx. Most participants had favorable clinical outcomes and microbiological response at test of cure. [Figure: see text] [Figure: see text] CONCLUSION: Plasma concentrations of CAZ and AVI after single and multiple doses of CAZ-AVI were similar to previous pediatric studies. Single and multiple doses of CAZ-AVI were safe and well tolerated in hospitalized neonates and young infants with suspected/confirmed bacterial infections. TEAEs were mild/moderate in severity and no new safety concerns were identified. DISCLOSURES: Emmanuel Roilides, MD, PhD, Gilead: Advisor/Consultant|GSK: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|Mundipharma: Advisor/Consultant|Pfizer: Grant/Research Support|Scynexis: Grant/Research Support Richard England, MD, PhD, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Margaret Tawadrous, MD, MS, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Jean Yan, M.S., Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Elena Soto, PhD, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Gregory Stone, PhD, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Shweta Kamat, MD, Pfizer: Employee of Pfizer|Pfizer: Stocks/Bonds Oxford University Press 2023-11-27 /pmc/articles/PMC10678973/ http://dx.doi.org/10.1093/ofid/ofad500.2473 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Bradley, John S Roilides, Emmanuel England, Richard Tawadrous, Margaret Yan, Jean Soto, Elena Stone, Gregory Kamat, Shweta 2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial |
title | 2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial |
title_full | 2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial |
title_fullStr | 2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial |
title_full_unstemmed | 2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial |
title_short | 2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial |
title_sort | 2890. pharmacokinetics, safety, and efficacy of ceftazidime-avibactam in neonates and young infants with bacterial infections: results from a phase 2a, 2-part, open-label, non-randomized, multicenter trial |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678973/ http://dx.doi.org/10.1093/ofid/ofad500.2473 |
work_keys_str_mv | AT bradleyjohns 2890pharmacokineticssafetyandefficacyofceftazidimeavibactaminneonatesandyounginfantswithbacterialinfectionsresultsfromaphase2a2partopenlabelnonrandomizedmulticentertrial AT roilidesemmanuel 2890pharmacokineticssafetyandefficacyofceftazidimeavibactaminneonatesandyounginfantswithbacterialinfectionsresultsfromaphase2a2partopenlabelnonrandomizedmulticentertrial AT englandrichard 2890pharmacokineticssafetyandefficacyofceftazidimeavibactaminneonatesandyounginfantswithbacterialinfectionsresultsfromaphase2a2partopenlabelnonrandomizedmulticentertrial AT tawadrousmargaret 2890pharmacokineticssafetyandefficacyofceftazidimeavibactaminneonatesandyounginfantswithbacterialinfectionsresultsfromaphase2a2partopenlabelnonrandomizedmulticentertrial AT yanjean 2890pharmacokineticssafetyandefficacyofceftazidimeavibactaminneonatesandyounginfantswithbacterialinfectionsresultsfromaphase2a2partopenlabelnonrandomizedmulticentertrial AT sotoelena 2890pharmacokineticssafetyandefficacyofceftazidimeavibactaminneonatesandyounginfantswithbacterialinfectionsresultsfromaphase2a2partopenlabelnonrandomizedmulticentertrial AT stonegregory 2890pharmacokineticssafetyandefficacyofceftazidimeavibactaminneonatesandyounginfantswithbacterialinfectionsresultsfromaphase2a2partopenlabelnonrandomizedmulticentertrial AT kamatshweta 2890pharmacokineticssafetyandefficacyofceftazidimeavibactaminneonatesandyounginfantswithbacterialinfectionsresultsfromaphase2a2partopenlabelnonrandomizedmulticentertrial |